Correlation of anti-C1q antibodies with active systemic lupus erythematosus and lupus nephritis in children

LI Yong-Zhen; YANG Jin-Rong; ZHANG Yu-Di; CAO Yan; LI Xiao-Yan; SHUAI Lan-Jun; WANG Ying; SHEN Tian; WU Xiao-Chuan

doi:10.7499/j.issn.1008-8830.2404159

PDF(522 KB)

Chinese Journal of Contemporary Pediatrics ›› 2024, Vol. 26 ›› Issue (8) : 835-839. DOI: 10.7499/j.issn.1008-8830.2404159

CLINICAL RESEARCH

Correlation of anti-C1q antibodies with active systemic lupus erythematosus and lupus nephritis in children

LI Yong-Zhen, YANG Jin-Rong, ZHANG Yu-Di, CAO Yan, LI Xiao-Yan, SHUAI Lan-Jun, WANG Ying, SHEN Tian, WU Xiao-Chuan

Author information +

History +

Abstract

Objective To study the correlation of anti-C1q antibodies with active systemic lupus erythematosus (SLE) and lupus nephritis (LN) in children, as well as their diagnostic value for active SLE and LN. Methods A retrospective selection of 90 hospitalized children with SLE at the Children's Medical Center of Second Xiangya Hospital, Central South University from January 2016 to March 2019 as the SLE group, all of whom were tested for anti-C1q antibodies. A control group was formed by collecting 70 hospitalized children with other autoimmune diseases (OAD) during the same period. The differences in anti-C1q antibody levels were compared between two groups.The correlation of anti-C1q antibodies with various indicators of SLE and LN was analyzed, and the diagnostic value of anti-C1q in SLE and LN was evaluated. Results The serum levels of anti-C1q antibodies in the SLE group were higher than those in the OAD group (P<0.05). The SLE disease activity index score was positively correlated with anti-C1q antibodies (r_s=0.371, P<0.001) and positively correlated with anti-double-stranded DNA antibodies (r_s=0.370, P<0.001). The sensitivity and specificity of anti-C1q antibodies for diagnosing active SLE were 89.90% and 53.90%, respectively, with an area under the curve of 0.720 (P<0.05) and a critical value of 5.45 U/mL. The sensitivity and specificity of anti-C1q antibody levels for diagnosing active LN were 58.50% and 85.00%, respectively, with an area under the curve of 0.675 (P<0.05) and a critical value of 22.05 U/mL. Conclusions Anti-C1q antibodies can serve as non-invasive biomarkers for evaluating the activity of SLE or predicting the activity of LN in children.

Key words

Systemic lupus erythematosus / Lupus nephritis / Anti-C1q antibody / Activity / Child

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

LI Yong-Zhen, YANG Jin-Rong, ZHANG Yu-Di, CAO Yan, LI Xiao-Yan, SHUAI Lan-Jun, WANG Ying, SHEN Tian, WU Xiao-Chuan. Correlation of anti-C1q antibodies with active systemic lupus erythematosus and lupus nephritis in children[J]. Chinese Journal of Contemporary Pediatrics. 2024, 26(8): 835-839 https://doi.org/10.7499/j.issn.1008-8830.2404159

References

1 Charras A, Smith E, Hedrich CM. Systemic lupus erythematosus in children and young people[J]. Curr Rheumatol Rep, 2021, 23(3): 20. PMID: 33569643. PMCID: PMC7875946. DOI: 10.1007/s11926-021-00985-0.
2 Wenderfer SE, Eldin KW. Lupus nephritis[J]. Pediatr Clin North Am, 2019, 66(1): 87-99. PMID: 30454753. DOI: 10.1016/j.pcl.2018.08.007.
3 宋红梅. 儿童风湿病国际相关诊治指南系列解读之一——EULAR-ACR系统性红斑狼疮分类标准解读[J]. 中国实用儿科杂志, 2020, 35(4): 249-252. DOI: 10.19538/j.ek2020040601.
4 Alforaih N, Whittall-Garcia L, Touma Z. A review of lupus nephritis[J]. J Appl Lab Med, 2022, 7(6): 1450-1467. PMID: 35932197. DOI: 10.1093/jalm/jfac036.
5 Kleer JS, Rabatscher PA, Weiss J, et al. Epitope-specific anti-C1q autoantibodies in systemic lupus erythematosus[J]. Front Immunol, 2022, 12: 761395. PMID: 35087514. PMCID: PMC8788646. DOI: 10.3389/fimmu.2021.761395.
6 Emad G, Al-Barshomy SM. Anti-C1q antibodies in lupus nephritis and their correlation with the disease activity[J]. Saudi J Kidney Dis Transpl, 2020, 31(2): 342-352. PMID: 32394906. DOI: 10.4103/1319-2442.284008.
7 Radanova M, Vasilev V, Mihaylova G, et al. Autoantibodies against complement classical pathway components C1q, C1r, C1s and C1-Inh in patients with lupus nephritis[J]. Int J Mol Sci, 2022, 23(16): 9281. PMID: 36012546. PMCID: PMC9409282. DOI: 10.3390/ijms23169281.
8 Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus[J]. Ann Rheum Dis, 2019, 78(9): 1151-1159. PMID: 31383717. DOI: 10.1136/annrheumdis-2018-214819.
9 党西强, 易著文. 狼疮性肾炎诊治循证指南（2016）解读[J]. 中华儿科杂志, 2018, 56(2): 95-99. PMID: 29429195. DOI: 10.3760/cma.j.issn.0578-1310.2018.02.004.
10 Kianmehr N, Khoshmirsafa M, Shekarabi M, et al. High frequency of concurrent anti-C1q and anti-dsDNA but not anti-C3b antibodies in patients with lupus nephritis[J]. J Immunoassay Immunochem, 2021, 42(4): 406-423. PMID: 33788670. DOI: 10.1080/15321819.2021.1895215.
11 Shang X, Ren L, Sun G, et al. Anti-dsDNA, anti-nucleosome, anti-C1q, and anti-histone antibodies as markers of active lupus nephritis and systemic lupus erythematosus disease activity[J]. Immun Inflamm Dis, 2021, 9(2): 407-418. PMID: 33470559. PMCID: PMC8127563. DOI: 10.1002/iid3.401.
12 Carlucci F, Ishaque A, Ling GS, et al. C1q modulates the response to TLR7 stimulation by pristane-primed macrophages: implications for pristane-induced lupus[J]. J Immunol, 2016, 196(4): 1488-1494. PMID: 26773156. PMCID: PMC4745139. DOI: 10.4049/jimmunol.1401009.
13 Oni L, Wright RD, Marks S, et al. Kidney outcomes for children with lupus nephritis[J]. Pediatr Nephrol, 2021, 36(6): 1377-1385. PMID: 32725543. PMCID: PMC8084759. DOI: 10.1007/s00467-020-04686-1.
14 Trendelenburg M, Schifferli JA. Apoptosis and C1q: possible explanations for the pathogenesis of systemic lupus erythematosus[J]. Z Rheumatol, 2000, 59(3): 172-175. PMID: 10929445. DOI: 10.1007/s003930070077.
15 Dias R, Hasparyk UG, Lopes MP, et al. Novel biomarkers for lupus nephritis in the "OMICS" era[J]. Curr Med Chem, 2021, 28(29): 6011-6044. PMID: 33583367. DOI: 10.2174/0929867328666210212102438.
16 Meyer OC, Nicaise-Roland P, Cadoudal N, et al. Anti-C1q antibodies antedate patent active glomerulonephritis in patients with systemic lupus erythematosus[J]. Arthritis Res Ther, 2009, 11(3): R87. PMID: 19515233. PMCID: PMC2714141. DOI: 10.1186/ar2725.
17 Mosaad YM, Hammad A, Fawzy Z, et al. C1q rs292001 polymorphism and C1q antibodies in juvenile lupus and their relation to lupus nephritis[J]. Clin Exp Immunol, 2015, 182(1): 23-34. PMID: 26095468. PMCID: PMC4578505. DOI: 10.1111/cei.12666.
18 Zhang CQ, Ren L, Gao F, et al. Anti-C1q antibodies are associated with systemic lupus erythematosus disease activity and lupus nephritis in northeast of China[J]. Clin Rheumatol, 2011, 30(7): 967-973. PMID: 21340499. DOI: 10.1007/s10067-011-1698-1.
19 Gargiulo MLá, Khoury M, Gómez G, et al. Cut-off values of immunological tests to identify patients at high risk of severe lupus nephritis[J]. Medicina (B Aires), 2018, 78(5): 329-335. PMID: 30285925.
20 Sun J, Guo S, Niu F, et al. Complement 1q protects MRL/lpr mice against lupus nephritis via inhibiting the nuclear factor-κB pathway[J]. Mol Med Rep, 2020, 22(6): 5436-5443. PMID: 33173997. DOI: 10.3892/mmr.2020.11588.